Tryptophan metabolism in rat liver after administration of tryptophan, kynurenine metabolites, and kynureninase inhibitors

International Journal of Tryptophan Research

Volumn 9, Issue 1, 2016, Pages 51-65

  Badawy, Abdulla A B ^a   Bano, Samina ^a,b  

^a CARDIFF METROPOLITAN UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

3 dioxygenase; Kynureninase; Kynurenine aminotransferase; Kynurenine pathway; Tryptophan 2

Indexed keywords

EID: 85009841641     PISSN: None     EISSN: 11786469     Source Type: Journal    
DOI: 10.4137/IJTR.S38190     Document Type: Article

References (47)

1. Badawy AA-B, Bano S. Elevation of kynurenine metabolites in rat liver and serum: a potential additional mechanism of the alcohol aversive and anti-cancer effects of disulfiram? Alcohol Alcohol. 2016;51:20-5.
2. Bender DA. Biochemistry of tryptophan in health and disease. Mol Aspects Med. 1983;6:1-97.
3. Badawy AA-B. Tryptophan metabolism in alcoholism. Nutr Res Rev. 2002;1: 123-52.
4. Badawy AA-B. Tryptophan metabolism, disposition and utilization in pregnancy. Biosci Rep. 2015;35:e00261.
5. Moffett JR, Namboodiri MA. Tryptophan and the immune response. Immunol Cell Biol. 2003;81:247-65.
6. Yeung AWS, Terentis AC, King NCJ, Thomas SR. Role of indoleamine 2, 3-dioxygenase in health and disease. Clin Sci. 2015;129:601-72.
7. Badawy AA-B, Namboodiri AMA, Moffett JR. Hypothesis: the end of the road for the tryptophan depletion concept in pregnancy and infection. Clin Sci (Lond). 2016;130(15):1327-33.
8. Stone TW, Darlington LG. Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov. 2002;1:1-13.
9. Chen Y, Guillemin GJ. Kynurenine pathway metabolites in humans: disease and healthy states. Int J Tryptophan Res. 2009;2:1-19.
10. Badawy AA-B, Bano S, Steptoe A. Tryptophan in alcoholism treatment I: kynurenine metabolites inhibit the rat liver mitochondrial low Km aldehyde dehydrogenase activity, elevate blood acetaldehyde concentration and induce aversion to alcohol. Alcohol Alcohol. 2011;46:651-60.
11. Badawy AA-B, Bano S, Steptoe A. Tryptophan in alcoholism treatment II: inhibition of the rat liver mitochondrial low Km aldehyde dehydrogenase activity, elevation of blood acetaldehyde concentration and induction of aversion to alcohol by combined administration of tryptophan and benserazide. Alcohol Alcohol. 2011;46:661-71.
12. Badawy AA-B, Morgan CJ. Rapid isocratic liquid chromatographic separation and quantification of tryptophan and six kynurenine metabolites in biological samples with ultraviolet and fluorimetric detection. Int J Tryptophan Res. 2010;3:175-86.
13. Murachi T, Tsukada K, Hayaishi O. Metabolic fate of kynurenic acid C14 intraperitoneally administered to animals. Biochemistry. 1963;2:304-8.
14. Taniuchi H, Hayaishi O. Studies on the metabolism of kynurenic acid III. Enzymatic formation of 7, 8-dihydroxykynurenic acid from kynurenic acid. J Biol Chem. 1963;238:283-93.
15. Moroni F, Cozzi A, Sili M, Mannaioni G. Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. J Neural Transm. 2012;119:133-9.
16. Malaczewska J, Siwicki AK, Wójcik RM, Turski WA, Kaczorek E. The effect of kynurenic acid on the synthesis of selected cytokines by murine splenocytes-in vitro and ex vivo studies. Exp Immunol. 2016;41(1):39-46.
17. Linderholm KR, Skogh E, Olsson SK, et al. Increased levels of kynurenine and kynurenic acid in the CSF acid in the CSF of patients with schizophrenia. Schizophrenia Bull. 2012;3:426-32.
18. Stone W. The neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev. 1993;45:309-85.
19. Schwarcz R, Tamminga CA, Kurlan R, Shoulson I. Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia. Ann Neurol. 1988;24:580-2.
20. Darlington LG, Forrest CM, Mackay GM, et al. On the biological importance of the 3-hydroxyanthranilic acid: anthranilic acid ratio. Int J Tryptophan Res. 2010;3:51-9.
21. Darlington LG, Mackay GM, Forrest CM, Stoy N, George C, Stone TW. Altered kynurenine metabolism correlates with infarct volume in stroke. Eur J Neurosci. 2007;26:2211-21.
22. Oxenkrug G, van der Hart M, Roeser J, Summergrad P. Anthranilic acid: a potential biomarker and treatment target for schizophrenia. Ann Psychiatry Ment Health. 2016;4:1059.
23. Miller CL, Llenos IC, Cwik M, Walkup J, Weis S. Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder. Neurochem Int. 2008;52:1297-303.
24. Walsh HA, Botting NP. Purification and biochemical characterization of some of the of some of the properties of recombinant human kynureninase. Eur J Biochem. 2002;269:2069-74.
25. Okuno E, Schmidt W, Parks DA, Nakamura M, Schwarcz R. Measurement of rat brain kynurenine aminotransferase at physiological kynurenine concentrations. J Neurochem. 1991;57:533-40.
26. Wagner C. Regulation of the tryptophan-nicotinic acid DPN pathway in the rat. Biochem Biophys Res Commun. 1964;17:668-73.
27. Tanizawa K, Soda K. Inducible and constitutive kynureninases: control of the Inducible enzyme activity by transamination and inhibition of the constitutive enzyme by 3-hydroxyanthranilate. J Biochem. 1979;86:499-508.
28. Badawy AA-B, Evans M. The regulation of rat liver tryptophan pyrrolase by its cofactor haem-experiments with haematin and 5-aminolaevulinate and comparison with the substrate and hormonal mechanisms. Biochem J. 1975;150:511-20.
29. Takeuchi F, Shibata Y. Kynurenine metabolism in vitamin-B-6-deficient rat liver after tryptophan injection. Biochem J. 1984;220:693-9.
30. Badawy AA-B, Dougherty DM. Assessment of the human kynurenine pathway: comparisons and clinical implications of ethnic and gender differences in plasma tryptophan, kynurenine metabolites and enzyme expressions at baseline and after acute tryptophan loading and depletion. Int J Tryptophan Res. 2016;9. [in press].
31. Bender DA, Smith WRD, Humm RP. Effects of benserazide on tryptophan metabolism in the mouse. Biochem Pharmacol. 1977;26:1619-23.
32. Bender DA. Inhibition in vitro of the enzymes of the oxidative pathway of tryptophan metabolism and of nicotinamide nucleotide synthesis by benserazide, carbidopa and isoniazid. Biochem Pharmacol. 1980;29:707-12.
33. Young SN, St-Arnaud-McKenzie D, Sourkes TL. Importance of tryptophan pyrrolase and aromatic amino acid decarboxylase in the catabolism of tryptophan. Biochem Pharmacol. 1977;27:763-7.
34. Bender DA, Smith WRD. Inhibition of kynurenine hydroxylase by benserazide, carbidopa and other aromatic hydrazine derivatives: evidence for subclinical iatrogenic niacin deficiency. Biochem Soc Trans. 1978;6:120-2.
35. Chiarugi A, Carpenedo R, Molina MT, Mattoli L, Pellicciari R, Moroni F. Comparison of the neurochemical and behavioral effects resulting from the inhibition of kynurenine hydroxylase and kynureninase. J Neurochem. 1995;65:1176-83.
36. Satoh T. Activation of tryptophan pyrrolase by benzylhydrazine. Acta Vitaminol Enzymol. 1975;29:283-6.
37. Cho-Chung YS, Pitot HC. Feedback control of rat liver tryptophan pyrrolase I. End product inhibition of tryptophan pyrrolase activity. J Biol Chem. 1967; 212:1192-8.
38. Hardeland R. Complexity of in vivo induction of tryptophan oxygenase and tyrosine aminotransferase: effects of tryptophan metabolites. Comp Biochem Physiol. 1972;41B:39-44.
39. Levkovitz Y, Ophir-Shaham O, Bloch Y, Treves I, Fennig S, Grauer E. Effect of L-tryptophan on memory in patients with schizophrenia. J Nerv Ment Dis. 2003;191:568-73.
40. Gillin JC, Kaplan JA, Wyatt RJ. Clinical effects of tryptophan in chronic schizophrenic patients. Biol Psychiat. 1976;11:635-9.
41. Rosse RB, Schwartz BL, Zlotolow S, et al. Effect of a low-tryptophan diet as an adjuvant to conventional neuroleptic therapy in schizophrenia. Clin Neuropharmacol. 1992;15:129-41.
42. Wu H-Q, Okuyama M, Kajii Y, Pocivavsek A, Bruno JP, Schwarcz R. Targeting kynurenine aminotransferase II in psychiatric diseases: promising effect of an orally active enzyme inhibitor. Schizophrenia Bull. 2014;40(suppl 2):S2152-8.
43. Chouinard G, Annable L, Serrano M, Charette R. A controlled study of a dopa decarboxylase inhibitor (benserazide) in the treatment of schizophrenic patients. Int Pharmacopsychiatry. 1977;12:1-8.
44. Chouinard G, Annable L, Young SN, Sourkes TL. A controlled study of tryptophan-benserazide in schizophrenia. Commun Psychopharmacol. 1978;2: 21-31.
45. Malaczewska J, Siwicki AK, Wójcik RM, Turski WA, Kaczorek E. The effect of kynurenic acid on the synthesis of selected cytokines by murine splenocytes-in vitro and ex vivo studies. Cent Eur J Immunol. 2016;41:39-46.
46. Wirthgen E, Kanitz E, Tuchscherer M, et al. Pharmacokinetics of 1-methyl-L-tryptophan after single and repeated subcutaneous application in a porcine model. Exp Anim. 2016;65:147-55.
47. Too LK, Li KM, Suarna C, et al. Deletion of TDO2, IDO-1 and IDO-2 differentially affects mouse behavior and cognitive function. Behav Brain Res. 2016;312:102-17.